Towards Healthcare
Pediatric Drugs Market Size Envisioned at USD 363.86 Billion by 2032

Pediatric Drugs Market Size Envisioned at USD 363.86 Billion by 2032

Status: Published Category: Therapeutic Area Insight Code: 5074 Format: PDF / PPT / Excel

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Pediatric Drugs Market Assessment

  • Overview
  • Global Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Antibiotic
    • Analgesic
    • Antipyretic
    • Respiratory Drugs
    • Gastrointestinal Drugs
    • Central nervous system Drugs
    • Vaccines
    • Others
  • Global Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Parenteral
  • Global Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies 
  • Global Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Middle East & Africa (MEA)
      • Saudi Arabia
      • UAE
      • South Africa
      • Rest of the Middle East & Africa

North America Pediatric Drugs Market Assessment

  • Overview
  • North America Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Antibiotic
    • Analgesic
    • Antipyretic
    • Respiratory Drugs
    • Gastrointestinal Drugs
    • Central nervous system Drugs
    • Vaccines
    • Others
  • North America Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Parenteral
  • North America Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies 
  • North America Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Country (2021 – 2033)
    • U.S.
    • Canada

Europe Pediatric Drugs Market Assessment

  • Overview
  • Europe Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Antibiotic
    • Analgesic
    • Antipyretic
    • Respiratory Drugs
    • Gastrointestinal Drugs
    • Central nervous system Drugs
    • Vaccines
    • Others
  • Europe Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Parenteral
  • Europe Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Europe Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Country (2021 – 2033)
    • U.K.
    • Germany
    • France
    • Rest of Europe

Asia-Pacific Pediatric Drugs Market Assessment

  • Overview
  • Asia-Pacific Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Antibiotic
    • Analgesic
    • Antipyretic
    • Respiratory Drugs
    • Gastrointestinal Drugs
    • Central nervous system Drugs
    • Vaccines
    • Others
  • Asia-Pacific Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Parenteral
  • Asia-Pacific Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies 
  • Asia-Pacific Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Country (2021 – 2033)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific

Latin America Pediatric Drugs Market Assessment

  • Overview
  • Latin America Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Antibiotic
    • Analgesic
    • Antipyretic
    • Respiratory Drugs
    • Gastrointestinal Drugs
    • Central nervous system Drugs
    • Vaccines
    • Others
  • Latin America Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Parenteral
  • Latin America Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies 
  • Latin America Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Country (2021 – 2033)
    • Brazil
    • Rest of Latin America

Middle East & Africa (MEA) Pediatric Drugs Market Assessment

  • Overview
  • Middle East & Africa (MEA) Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Antibiotic
    • Analgesic
    • Antipyretic
    • Respiratory Drugs
    • Gastrointestinal Drugs
    • Central nervous system Drugs
    • Vaccines
    • Others
  • Middle East & Africa (MEA) Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Parenteral
  • Middle East & Africa (MEA) Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies 
  • Middle East & Africa (MEA) Pediatric Drugs Market Size Value (US$) and Volume (Billion Tons), by Country (2021 – 2033)
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of the Middle East & Africa

Company Profiles

  • Pfizer Inc.
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Novartis International AG
  • GSK plc.
  • Sanofi S.A.
  • AstraZeneca plc
  • Merck & Co.,Inc.
  • Johnson & Johnson
  • Roche Holding AG
  • Eli Lilly and Company
  • Abbott Laboratories

Conclusion & Recommendations

  • Insight Code: 5074
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: December 2023
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of experience specializing in the healthcare sector. His expertise spans various facets of healthcare, including market dynamics, emerging trends, regulatory changes, and technology-driven innovations. With a keen eye for detail and a deep understanding of the global healthcare landscape, Rohan has been instrumental in shaping actionable insights that guide healthcare organizations in making informed, data-driven decisions.

Rohan's extensive experience covers a wide range of healthcare segments, from pharmaceuticals and biotechnology to medical devices and digital health. He has worked on numerous projects that evaluate market potential, assess competitive landscapes, and identify growth opportunities in rapidly evolving sectors in the healthcare industry.

His analytical acumen and ability to synthesize complex data have made him a trusted advisor to healthcare companies, helping them navigate the challenges and opportunities within the healthcare ecosystem. Rohan is particularly passionate about how technology and innovation are reshaping healthcare delivery, and his reports provide valuable insights into the impact of digital transformation on patient care, outcomes, and cost-efficiency.

With a strong track record in healthcare market research, Rohan continues to contribute significantly to the advancement of the industry by delivering data-backed strategies and comprehensive market analysis.

FAQ's

The propulsion of the pediatric drugs market emanates from the escalating prevalence of pediatric health concerns and the growing incidence of childhood ailments. These pivotal factors collectively contribute to a heightened demand for pharmaceutical interventions tailored specifically to address the unique medical needs of the pediatric population. As the landscape of pediatric healthcare evolves, marked by a surge in pediatric health issues, there is a discernible necessity for specialized therapeutic solutions. The imperative further shapes the market trajectory to develop and make available pharmaceutical interventions that ensure the safety and efficacy requisite for pediatric patients, constituting a pivotal facet of the contemporary healthcare landscape.

Prominent participants in the pediatric drugs market include Pfizer Inc., GSK, Novartis AG, Sanofi, AstraZeneca, Merck & Co., Johnson & Johnson, Roche Holding AG, Teva Pharmaceutical Industries, Eli Lilly and Company, Bristol-Myers Squibb, Novo Nordisk A/S, Boehringer Ingelheim, Takeda Pharmaceutical Company, AbbVie Inc., among others.

The pediatric sector encounters challenges due to smaller patient populations and limited exclusivity periods, making it more difficult to justify allocating resources for research and development. This limitation mainly affects the development of drugs for rare pediatric diseases, where patient numbers are exceptionally restricted.

National Institute of Health, World Health Organisation, United Nations Office on Drug and Crime, Food and Drug Administration.gov, The National Academies Press

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 515

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 515